- Report
- May 2024
- 133 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1365EUR$1,500USD£1,160GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €1138EUR$1,250USD£966GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- August 2022
- 109 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,049GBP
Econazole is an antifungal drug used to treat a variety of infectious diseases. It is a broad-spectrum antifungal agent, meaning it is effective against a wide range of fungi. It is commonly used to treat fungal infections of the skin, nails, and mucous membranes. It is also used to treat systemic fungal infections, such as those caused by Candida species. Econazole is available in both topical and oral formulations.
The market for econazole is driven by the increasing prevalence of fungal infections, as well as the growing demand for antifungal drugs. The rising prevalence of drug-resistant fungal infections is also driving the market. The increasing prevalence of HIV/AIDS and other immunocompromised conditions is also contributing to the growth of the econazole market.
Some of the major companies in the econazole market include Pfizer, Merck, Novartis, GlaxoSmithKline, and Bayer. These companies are engaged in the development, manufacture, and marketing of econazole-based products. Show Less Read more